Drug intelligence / Profile preview

XVIE

Development stage: Phase 2
Lead developer: Restore Biologics Holdings
Modality: Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

XVIE is a human amniotic fluid-derived nanoparticle solution, specifically an Acellular Allogenic Human Amniotic Fluid (hAF). It is being investigated in a pilot study to evaluate its efficacy and safety for improving hair growth in women experiencing self-perceived thinning hair. The solution is applied to the scalp via microneedling.

Brand names: Xtressé
Other names: decellularized allogeneic human amniotic fluidhAF

Beyond the preview

Go deeper on XVIE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XVIE.

Explore the full profile